Benitec Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Benitec Biopharma (BNTC).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

3S.Buy

9Buy

Consensus RatingOutperform# Analysts12Avg. Consensus PT$22Upside to Avg. PT+153.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 23, 2026	Raymond James	Tiago Fauth	Initiate	Outperform	$14
Sep 15, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$16→$17
Jul 28, 2026	Wedbush	Yun Zhong	Initiate	Outperform	$16
May 12, 2026	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$25
Mar 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$32
Nov 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$35→$32
Nov 4, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$28→$35
Nov 4, 2025	Citizens	Silvan Tuerkcan	PT Raise	Market Outperform	$20→$22
Sep 24, 2025	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$20
Sep 16, 2025	Oppenheimer	Andreas Argyrides	PT Cut	Outperform	$35→$29
May 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$28
May 15, 2025	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$20
Apr 10, 2025	JMP Securities	Silvan Tuerkcan	PT Raise	Market Outperform	$18→$20
Mar 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$28
Mar 18, 2025	Citizens Capital Markets	Silvan Tuerkcan	Maintained	Market Outperform	$18
Feb 21, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$28
Dec 13, 2024	Baird	Brian Skorney	Initiate	Outperform	$30
Dec 3, 2024	Guggenheim	Debjit Chattopadhyay	Maintained	Buy	$17
Oct 16, 2024	Oppenheimer	Andreas Argyrides	Initiate	Outperform	$35
Oct 14, 2024	JMP Securities	Silvan Tuerkcan	PT Raise	Market Outperform	$16→$18

Analyst Ratings News

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.

Avi Kapoor

PRO
Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.

Benzinga Newsdesk

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.

Avi Kapoor

PRO
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

Evercore ISI Group analyst Cory Kasimov initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $25.

Benzinga Newsdesk

Benitec Biopharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Benitec Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

PRO
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

PRO
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

People Also Watch

People Also Watch

Benitec Biopharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Benitec Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRORaymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

PROWedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROWedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

PROEvercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

People Also Watch

People Also Watch

PRO
Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14

PRO
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

PRO
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

PRO
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25